PT - JOURNAL ARTICLE AU - Nicholas, Ben AU - Guo, Jane AU - Lee, Hyun-Hee AU - Bailey, Alistair AU - de Waal Malefyt, Rene AU - Cicmil, Milenko AU - Djukanovic, Ratko TI - Analysis of cell-specific peripheral blood biomarkers in severe allergic asthma identifies innate immune dysfunction AID - 10.1101/2022.01.12.22268892 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.12.22268892 4099 - http://medrxiv.org/content/early/2022/03/10/2022.01.12.22268892.short 4100 - http://medrxiv.org/content/early/2022/03/10/2022.01.12.22268892.full AB - Asthma is a disease of complex origin and multiple pathologies. There are currently very few biomarkers of proven utility in its diagnosis, management or response to treatment. Recent studies have identified multiple asthma phenotypes following biofluid analysis; however, such findings may be driven by the well-characterised alterations in immune cell populations in asthma. We present a study designed to identify cell type-specific gene signatures of severe allergic asthma in peripheral blood samples. Using transcriptomic profiling of four magnetically purified peripheral blood cell types, we identify significant gene expression changes in monocytes and NK cells but not T lymphocytes in severe asthmatics. Pathway analysis indicates dysfunction of immune cell regulation and bacterial suppression in the NK cells. These gene expression changes may be useful on their own as prognostic peripheral blood cell markers of severe asthma, but also may indicate novel cell pathways for therapeutic intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a collaboration between the University of Southampton and Merck & Co Inc. Merck & Co Inc. assisted in the design of the work and the collection, analysis, and interpretation of data. The manuscript was conceived and written by the University of Southampton co-authors and was approved by co-authors from Merck & Co Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the regional Research Ethics Committee (REC), (Southampton and South West Hampshire Research Ethics Committee, LREC no: 09/H0504/109) and was conducted in accordance with Site Specific Assessment (SSA), and local Research and Development (R&D) approvals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript